Anti-Cannabinoid Receptor 2 (extracellular)
- 貨號 Cat. No.
- ACR-003
- 規格 Size
- 50 μl 0.2ml
Description
Anti-Cannabinoid Receptor 2 (extracellular)
| Product#: | ACR-003 |
| Sizes: |
| 50 µl |
| 0.2 ml |
| Host: |
| Rabbit |
| Epitope: |
Peptide (C)NGSKDGLDSNPMKD corresponding to residues 11-24 of human Cannabinoid Receptor 2 (Accession P34972). |
 |
| Putative epitope location: |
| Extracellular, N-terminus. |
| Homology: |
Canis, bovine ?10/14 residues identical. |
| Reactivity Confirmed: |
| Human |
Applications:
| Western Blotting: |
HL-60 (human Promyelocytic leukemia) and MCF-7 (human adenocarcinoma, mammary gland) cell line lysates (1:200). |
 | Western blotting of HL-60 (lanes 1,2) and MCF-7 (lanes 3,4) cell line lysates: 1,3. Anti-CB2R (extracellular) antibody (#ACR-003) (1:200). 2,4. Anti-CB2R (extracellular) antibody, preincubated with the control peptide antigen. |
| Immunocytochemistry: |
Immunocytochemical staining of human prostate carcinoma (LNCaP). |
 |
LNCaP cells stained with Anti-CB2R (extracellular) antibody (#ACR-003) 1:50, followed by goat-anti-rabbit-AlexaFluor-480 secondary antibody. B. Nuclear staining of LNCaP cells with the cell permeable dye Hoechst 33342. C. Live intact LNCaP cells. |
| Flow Cytometry: |
| FACS analysis of live intact human HL-60 Promyelocytic leukemia cells: |
 |
___ HL-60 cells + Goat-anti-Rabbit-FITC alone. ___ HL-60 cells + Anti-CB2R (extracellular) antibody (5 mg) + Goat-anti-Rabbit-FITC |
| References: |
| 1. Brooks, J.W. and Fraquhar-Smith, M.A. (2003) Br. J. Anaesth. 3, 175. |
| 2. Howlett, A.C. (2002) Prostaglandins & other Lipid Mediators 68, 619. |
| 3. Guo, J. and Ikeda, S.R. (2004) Mol. Pharmacol. 65, 665. |
| 4. Wotherspoon, G. et al. (2005) Neuroscience 135, 235. |
| 5. Gong, J.P. et al. (2006) Brain Research 1071, 10. |
| 6. Fernandez-Ruiz, J. et al. (2007) Trends Pharmacol. Sci. 28, 39. |
| 7. Sarfaraz, S. et al.(2005) Cancer Res. 65, 1635. |
| 8. Så«•chez, C. et al.(2001) Cancer Res. 61, 5784. |
| 9. Jord? M.A.. et al.(2004) Blood 104, 526. |
Cannabinoids have been used as pain relievers in eastern medicine for many years.1 To date, two specific cannabinoid receptors have been identified: the Cannabinoid Receptor 1 (CB1R) and the Cannabinoid Receptor 2 (CB2R).2 The cannabinoid receptors can be distinguished by their amino acid sequence, signaling mechanisms and tissue distribution.2 Both receptors belong to the G-protein coupled receptor superfamily and are coupled to Gi/0 G protein.2,3
The CB2R is highly expressed in cells of the immune system such as macrophages, lymphocytes natural killer cells and mast cells but has also been shown to be expressed, by both, in situ-hybridization and in immunohistochemistry, in spleen, thymus, and pancreas.1,2,4 CB2R expression in brain is still much less characterized than that of CB1R. Recently, it was demonstrated that CB2R is expressed in brain and might have role in controlling fundamental processes such as proliferation and survival of neural cells.5,6
Overexpression of CB2R was reported in several cancers such as prostate, glioma and acute myeloid leukemias.7-9
In human astrocytoma a direct relation between CB2R expression and tumor malignancy was demonstrated.8 Activation of CB2R, in vivo, by its agonist JWH-133, completely blocked cell growth.8 In C6 glioma it was shown that activation of the CB2R by JWH-133 resulted in internalization of only the CB2R, and not CB1R leading to apoptosis of the cells. This may well be a new approach for the treatment of glioma.
Alomone is pleased to offer a new, extracellular antibody directed against the human CB2R, Anti-CB2 Receptor Antibody (#ACR-003).